Floatz logo

Obinutuzumab

Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS)

National Cancer Institute (NCI)monoclonal_antibodyPhase 1Active
CC
43/ 100
Provisional rating · Methodology v0.2

Rating breakdown

Clinical Evidence
28/ 100
Competitive Position
95/ 100

Competitive context

11 Active assets in the Primary Diffuse Large B-cell Lymphoma of the Central Nervous System (CNS) cohort.

Asset / SponsorPhaseRating
Nivolumab
National Cancer Institute (NCI)
Phase 2B
Pomalidomide
Mayo Clinic
Phase 1CCC
DEXAMETHASONE
National Cancer Institute (NCI)
Phase 1CC
IMMUNOGLOBULIN G1, ANTI-(HUMAN CD ANTIGEN CD27) (HUMAN MONOCLONAL CDX-1127 CLONE 1F5 HEAVY CHAIN), DISULFIDE WITH HUMAN MONOCLONAL CDX-1127 CLONE 1F5 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 2CC
IMMUNOGLOBULIN G 1 (HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .GAMMA.1-CHAIN ANTI-HUMAN ANTIGEN CD 20), DISULFIDE WITH HUMAN-MOUSE MONOCLONAL IDEC-C2B8 .KAPPA.-CHAIN, DIMER
National Cancer Institute (NCI)
Phase 1CC

View all 12 →

Same molecule, other indications

Obinutuzumab is also rated in:

Richter transformationDormant
BB
Indicative ·
71 / 100
View asset →
B-cell chronic lymphocytic leukemiaDormant
BB
Indicative ·
71 / 100
View asset →
chronic lymphocytic leukemia/small lymphocytic lymphomaDormant
BB
Indicative ·
69 / 100
View asset →

Need depth?

Order a full diligence report on this asset.

Order report →

Are you the sponsor?

Submit your data room for a Verified Rating. The public-data rating remains visible alongside.

Contact →